Last reviewed · How we verify
Influenza vaccination with PCV13
PCV13 (pneumococcal conjugate vaccine) stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating pneumococcal polysaccharide antigens to a protein carrier.
PCV13 (pneumococcal conjugate vaccine) stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating pneumococcal polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in adults aged 50 years and older, Prevention of invasive pneumococcal disease in children aged 2-59 months, Prevention of pneumococcal otitis media and pneumonia.
At a glance
| Generic name | Influenza vaccination with PCV13 |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
PCV13 works by presenting pneumococcal capsular polysaccharides conjugated to a diphtheria toxoid protein carrier, which enhances T-cell dependent immune responses. This approach converts the polysaccharide antigens into T-cell dependent antigens, resulting in improved antibody production, immunological memory, and protection against invasive pneumococcal disease caused by the 13 covered serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in adults aged 50 years and older
- Prevention of invasive pneumococcal disease in children aged 2-59 months
- Prevention of pneumococcal otitis media and pneumonia
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders (PHASE4)
- Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).
- Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab
- Influenza Vaccine and Pneumococcal Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccination with PCV13 CI brief — competitive landscape report
- Influenza vaccination with PCV13 updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI